Alps Advisors Inc Stoke Therapeutics, Inc. Transaction History

Alps Advisors Inc

$17.2 Billion
Q2 2025

A detailed history of Alps Advisors Inc transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 29,430 shares of STOK stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,430

Previous 39,890 26.22%

Holding current value

$1.02 Million

Previous $265,000 26.04%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 11, 2025	SELL	$5.9 - $11.84 $61,714 - $123,846	-10,460 Reduced 26.22%	29,430 $334,000
Q1 2025 Apr 30, 2025	SELL	$6.65 - $12.74 $19,551 - $37,455	-2,940 Reduced 6.86%	39,890 $265,000
Q4 2024 Feb 13, 2025	BUY	$10.8 - $13.92 $462,564 - $596,193	42,830 New	42,830 $472,000
Q3 2023 Nov 14, 2023	BUY	$3.78 - $11.99 $623 - $1,978	165 Added 0.51%	32,647 $128,000
Q2 2023 Aug 14, 2023	BUY	$7.93 - $13.82 $26,938 - $46,946	3,397 Added 11.68%	32,482 $345,000
Q1 2023 May 10, 2023	BUY	$7.65 - $10.38 $17,870 - $24,247	2,336 Added 8.73%	29,085 $242,000
Q4 2022 Feb 14, 2023	BUY	$7.07 - $15.69 $37,004 - $82,121	5,234 Added 24.33%	26,749 $246,000
Q3 2022 Nov 14, 2022	SELL	$12.56 - $22.53 $21,728 - $38,976	-1,730 Reduced 7.44%	21,515 $276,000
Q2 2022 Aug 11, 2022	SELL	$10.36 - $23.93 $156,933 - $362,491	-15,148 Reduced 39.46%	23,245 $307,000
Q1 2022 May 16, 2022	SELL	$17.19 - $26.1 $71,819 - $109,045	-4,178 Reduced 9.81%	38,393 $808,000
Q4 2021 Feb 09, 2022	SELL	$18.11 - $30.72 $44,604 - $75,663	-2,463 Reduced 5.47%	42,571 $1.02 Million
Q3 2021 Nov 15, 2021	SELL	$23.65 - $34.44 $78,447 - $114,237	-3,317 Reduced 6.86%	45,034 $1.15 Million
Q2 2021 Aug 11, 2021	BUY	$30.53 - $41.09 $1.48 Million - $1.99 Million	48,351 New	48,351 $1.63 Million

Others Institutions Holding STOK

# of Institutions

142

Shares Held

57M

Call Options Held

2.7K

Put Options Held

57.4K

View Full List

About Stoke Therapeutics, Inc.

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $1.37B
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

More about STOK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.

Account

Alps Advisors Inc Stoke Therapeutics, Inc. Transaction History